NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
BioNTech SE BNTX
9 fiscal years on record · EUR · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
€2.9B
▲ 4.3% vs FY2024
EPS · FY25
€-4.70
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-39.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
EUR 2.9B
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 40 cents on every revenue dollar this year.
Per share
EUR -4.70
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-49.0%
Net margin-39.6%
Return on assets-5.1%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+42.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−45.1%
+42.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.25B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
EUR 22.0B
total assets, end of FY2025
Total assetsEUR 22.0B
CashEUR 7.7B
Current ratio7.54×
History
9 fiscal years
Every figure from documents filed with the SEC · EUR
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue €B
2.9
2.8
3.8
17.3
19.0
0.5
0.1
0.1
0.1
Operating income €B
−1.4
−1.3
0.7
12.6
15.3
−0.1
−0.2
−0.1
−0.1
EBITDA €B
−1.3
−1.3
0.7
·
·
·
·
·
·
Income tax €B
0.1
−0.0
0.3
3.5
4.8
−0.2
−0.0
0.0
0.0
Net income €B
−1.1
−0.7
0.9
9.4
10.3
0.0
−0.2
−0.0
−0.1
EPS, diluted €
−4.70
−2.77
3.83
37.77
39.63
0.06
−0.85
·
·
Dividend / sh €
·
·
·
·
·
·
·
·
·
Payout %
·
−0
0
5
0
0
·
·
·
ROE %
·
·
·
·
·
3.1
−47.2
−18.0
·
Shares out B
0.25
0.24
0.24
0.24
0.24
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
26 of 26
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed